Advanced Search

 

Study ID Status Title Patient Level Data
104864/627 Completed An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients with Recurrent Platinum Sensitive Ovarian Cancer
104864/692 Completed A Study to Determine the Bioequivalence of an Oral Formulation of Topotecan Containing the Drug Substance Manufactured by New Process Relative to the Current Study Formulation of Topotecan in Patients with Advanced Solid Tumors
104864/902 Completed An Open-Label, Single-Arm, Phase II Study of IV Weekly (Days 1 and 8 every 21 days) HYCAMTIN in Combination with Carboplatin (Day 1 every 21 days) as Second-Line Therapy in Subjects with Potentially Platinum-Sensitive Relapsed Ovarian Cancer
104864/903 Completed An open-label phase II study of weekly intravenous Hycamtin and carboplatin as first-line treatment of chemonaive subjects with Extensive Disease Small Cell lung Cancer
104864-A/387 Completed An Open-Label, Multicentre, Randomised, Phase III Study Comparing Oral Topotecan to Intravenous Docetaxel in Patients with Pretreated Advanced Non Small Cell Lung Cancer
104864-A/389 Completed An Open-Label, Multicenter, Randomized, Phase III Study Comparing Oral Topotecan/Cisplatin versus Etoposide/Cisplatin as Treatment for Chemotherapy-naive Patients with Extensive Disease-Small Cell Lung Cancer.
104864-A/479 Completed An Open-Label, Multicentre, Randomised, Phase III Study Comparing Topotecan/Cisplatin and Topotecan/Etoposide versus Etoposide/Cisplatin as Treatment for Chemotherapy-naive Patients with Extensive Disease-Small Cell Lung Cancer
104865 Completed A study to evaluate the safety, tolerability, systemic pharmacokinetic profile and pharmacodynamics of single and repeat inhaled doses of GSK961081 in healthy subjects Study Listed on ClinicalStudyDataRequest.com
104871 Completed A multicentric study to compare the immunogenicity, safety & reactogenicity of GSK Biologicals' DTPa-IPV vaccine vs. co-administration of GSK's DTPa vaccine & Sanofi-Pasteurs' IPV vaccine at different injection sites, to healthy children Study Listed on ClinicalStudyDataRequest.com
104886 Completed Demonstrate the non-inferiority in term of cellular mediated immune response of GSK Biologicals' influenza candidate vaccines containing various adjuvants administered in elderly population (aged 65 years & older) vs Fluarix™ (known as alpha-Rix™ in Belgium) administered in adults (18-40 years) Study Listed on ClinicalStudyDataRequest.com
104887 Completed Evaluate reactogenicity & immunogenicity of adjuvanted influenza vaccine in elderly adults previously vaccinated with the same candidate vaccine. Fluarix™ administered in young & elderly adults will be used as reference Study Listed on ClinicalStudyDataRequest.com
104888 Completed A phase II/III, observer-blind, Multi-Country, Multi-Centre, randomized study to demonstrate the superiority in terms of immunogenicity of adjuvanted influenza vaccine administered in adults aged 50 years and older compared to Fluarix™ Study Listed on ClinicalStudyDataRequest.com
104916 Completed An open-label, single dose study to investigate the safety, tolerability and pharmacokinetics of 90mg of GW274150 in adult and elderly RA subjects.
104935 Completed Acute Liver Failure (ALF)-associated causal agents and outcome of patients aged from birth to 18 years in India (CMC Vellore, KEM Pune and PGI Chandigarh), a retrospective review, 2003–2005
104951 Completed Evaluate the immunogenicity & safety of GSK Biologicals’ HPV-16/18 L1/AS04 vaccine administered intramuscularly according to a 0,1,6 mth schedule in healthy female subjects aged 10–14 yrs Study Listed on ClinicalStudyDataRequest.com
104972 Completed A randomised (with respect to placebo), double-blind, placebo-controlled, adaptive dose ascending study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK315234A (a humanised monoclonal antibody to oncostatin M) in patients with active rheumatoid arthritis (RA) Study Listed on ClinicalStudyDataRequest.com
104977 Completed Non-inferiority of one formulation of GSK Biologicals' DTPw-HBV/Hib to 2 formulations of GSK Biologicals' DTPw-HBV/Hib with respect to the immune response to the PRP antigen, when administered to healthy infants at 6, 10, 14 weeks of age Study Listed on ClinicalStudyDataRequest.com
104988 Completed Comparison of the effects of rosiglitazone and glimepiride, both given in combination with metformin, on 24-hour glycemia in type 2 diabetes patients not controlled with metformin alone. A 3-month multicentre, randomized, parallel-group, open-label study.
105011 Completed A single blind, randomised, placebo controlled, single ascending dose study to evaluate the safety, tolerability and pharmacokinetics of GSK424887 in healthy male subjects and an open label Positron Emission Tomography study to evaluate the serotonin transporter and neurokinin- receceptor occupancy
105012 Completed Emotional processing in healthy male volunteers treated with GSK424887. A single centre, randomised, double-blind, placebo-controlled parallel group study Study Listed on ClinicalStudyDataRequest.com
105036 Completed A single-blind, randomized, placebo-controlled study to investigate the safety, tolerability, and potential effects on betamethasone pharmacokinetics of a co administered infusion of the new chemical entity (NCE) in healthy female subjects. Study Listed on ClinicalStudyDataRequest.com
105-039 Completed A bioequivalence study of the US 25 mg LAMICTAL® compressed tablets, UK 25 mg LAMICTAL® dispersible/chewable tablets, and US 25 mg LAMICTAL® dispersible/chewable caplets in normal volunteers.
105-040 Completed A Multicenter, Double-Blind, Placebo-Controlled, Parallel-Design Evaluation of LAMICTAL for Add-on Treatment of Partial Seizures in Pediatric Patients Study Listed on ClinicalStudyDataRequest.com
105043/011 Completed An Open-label, Multicenter, Adaptive Design, Pilot Trial to Examine the Safety and Effectiveness of Argatroban in Combination with Abciximab, a Platelet GP IIb/IIIa Receptor Antagonist in Patients Undergoing Non-urgent Percutaneous Coronary Intervention
105043/011_1 Completed An Open-label, Multicenter, Adaptive Design, Pilot Trial to Examine the Safety and Effectiveness of Argatroban in Combination with Abciximab, a Platelet GP IIb/IIIa Receptor Antagonist in Patients Undergoing Non-urgent Percutaneous Coronary Intervention (Part 2)

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.